About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Enhancing Synaptic Plasticity and Cognition in Schizophrenia

NCT01776112·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University Medical Center Goettingen

Age

18–55

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Male and female patients with the diagnosis of schizophrenia (based on ICD-10 criteria)
Age between 18 and 55
Verbal IQ ≥ 85
Stable psychopathology on constant medication for 2 weeks
Informed consent.

You may not be if

Patients, who are
not willing or able to participate in the sports program and cognitive training
reveal a significant worsening of psychopathology (based on an increase over 20% of the PANSS positive score)
have an organic mental disorder (such as intoxication or neurological disorders of the CNS)
suffer from instable somatic diseases
have an active substance abuse

The record

StatusCompleted

PhaseNo phase

Taking part66

StartedJan 2011

UpdatedMay 27, 2015

Conditions

Where1

Dept. of Psychiatry and Psychotherapy, University Medical Center Goettingen, Georg-August-University
Göttingen, Lower Saxony, Germany

Clareo Health | Enhancing Synaptic Plasticity and Cognition in Schizophrenia